These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

565 related articles for article (PubMed ID: 26847056)

  • 1. IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function.
    Vallera DA; Felices M; McElmurry R; McCullar V; Zhou X; Schmohl JU; Zhang B; Lenvik AJ; Panoskaltsis-Mortari A; Verneris MR; Tolar J; Cooley S; Weisdorf DJ; Blazar BR; Miller JS
    Clin Cancer Res; 2016 Jul; 22(14):3440-50. PubMed ID: 26847056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced ADCC and NK Cell Activation of an Anticarcinoma Bispecific Antibody by Genetic Insertion of a Modified IL-15 Cross-linker.
    Schmohl JU; Felices M; Taras E; Miller JS; Vallera DA
    Mol Ther; 2016 Aug; 24(7):1312-22. PubMed ID: 27157665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent Cytolytic Activity and Specific IL15 Delivery in a Second-Generation Trispecific Killer Engager.
    Felices M; Lenvik TR; Kodal B; Lenvik AJ; Hinderlie P; Bendzick LE; Schirm DK; Kaminski MF; McElmurry RT; Geller MA; Eckfeldt CE; Vallera DA; Miller JS
    Cancer Immunol Res; 2020 Sep; 8(9):1139-1149. PubMed ID: 32661096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated Cytotoxicity.
    Schmohl JU; Felices M; Oh F; Lenvik AJ; Lebeau AM; Panyam J; Miller JS; Vallera DA
    Cancer Res Treat; 2017 Oct; 49(4):1140-1152. PubMed ID: 28231426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL.
    Reusing SB; Vallera DA; Manser AR; Vatrin T; Bhatia S; Felices M; Miller JS; Uhrberg M; Babor F
    Cancer Immunol Immunother; 2021 Dec; 70(12):3701-3708. PubMed ID: 34398302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition.
    Wiernik A; Foley B; Zhang B; Verneris MR; Warlick E; Gleason MK; Ross JA; Luo X; Weisdorf DJ; Walcheck B; Vallera DA; Miller JS
    Clin Cancer Res; 2013 Jul; 19(14):3844-55. PubMed ID: 23690482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trispecific killer engager 161519 enhances natural killer cell function and provides anti-tumor activity against CD19-positive cancers.
    Cheng Y; Zheng X; Wang X; Chen Y; Wei H; Sun R; Tian Z; Sun H
    Cancer Biol Med; 2020 Nov; 17(4):1026-1038. PubMed ID: 33299651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDS.
    Sarhan D; Brandt L; Felices M; Guldevall K; Lenvik T; Hinderlie P; Curtsinger J; Warlick E; Spellman SR; Blazar BR; Weisdorf DJ; Cooley S; Vallera DA; Önfelt B; Miller JS
    Blood Adv; 2018 Jun; 2(12):1459-1469. PubMed ID: 29941459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets.
    Gleason MK; Ross JA; Warlick ED; Lund TC; Verneris MR; Wiernik A; Spellman S; Haagenson MD; Lenvik AJ; Litzow MR; Epling-Burnette PK; Blazar BR; Weiner LM; Weisdorf DJ; Vallera DA; Miller JS
    Blood; 2014 May; 123(19):3016-26. PubMed ID: 24652987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells.
    Arvindam US; van Hauten PMM; Schirm D; Schaap N; Hobo W; Blazar BR; Vallera DA; Dolstra H; Felices M; Miller JS
    Leukemia; 2021 Jun; 35(6):1586-1596. PubMed ID: 33097838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TriKEs and BiKEs join CARs on the cancer immunotherapy highway.
    Tay SS; Carol H; Biro M
    Hum Vaccin Immunother; 2016 Nov; 12(11):2790-2796. PubMed ID: 27322989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel CD19-targeted TriKE restores NK cell function and proliferative capacity in CLL.
    Felices M; Kodal B; Hinderlie P; Kaminski MF; Cooley S; Weisdorf DJ; Vallera DA; Miller JS; Bachanova V
    Blood Adv; 2019 Mar; 3(6):897-907. PubMed ID: 30890546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tetraspecific scFv construct provides NK cell mediated ADCC and self-sustaining stimuli via insertion of IL-15 as a cross-linker.
    Schmohl JU; Felices M; Todhunter D; Taras E; Miller JS; Vallera DA
    Oncotarget; 2016 Nov; 7(45):73830-73844. PubMed ID: 27650544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trispecific killer engager CD16xIL15xCD33 potently induces NK cell activation and cytotoxicity against neoplastic mast cells.
    Yun HD; Felices M; Vallera DA; Hinderlie P; Cooley S; Arock M; Gotlib J; Ustun C; Miller JS
    Blood Adv; 2018 Jul; 2(13):1580-1584. PubMed ID: 29980573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors.
    Marin V; Pizzitola I; Agostoni V; Attianese GM; Finney H; Lawson A; Pule M; Rousseau R; Biondi A; Biagi E
    Haematologica; 2010 Dec; 95(12):2144-52. PubMed ID: 20713459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD33 Delineates Two Functionally Distinct NK Cell Populations Divergent in Cytokine Production and Antibody-Mediated Cellular Cytotoxicity.
    Hejazi M; Zhang C; Bennstein SB; Balz V; Reusing SB; Quadflieg M; Hoerster K; Heinrichs S; Hanenberg H; Oberbeck S; Nitsche M; Cramer S; Pfeifer R; Oberoi P; Rühl H; Oldenburg J; Brossart P; Horn PA; Babor F; Wels WS; Fischer JC; Möker N; Uhrberg M
    Front Immunol; 2021; 12():798087. PubMed ID: 35058934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic applications: natural killer cells in the clinic.
    Miller JS
    Hematology Am Soc Hematol Educ Program; 2013; 2013():247-53. PubMed ID: 24319187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. hIL-15 gene-modified human natural killer cells (NKL-IL15) augments the anti-human hepatocellular carcinoma effect in vivo.
    Jiang W; Zhang C; Tian Z; Zhang J
    Immunobiology; 2014 Jul; 219(7):547-53. PubMed ID: 24721706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fc-engineered anti-CD33 monoclonal antibody potentiates cytotoxicity of membrane-bound interleukin-21 expanded natural killer cells in acute myeloid leukemia.
    Mani R; Rajgolikar G; Nunes J; Zapolnik K; Wasmuth R; Mo X; Byrd JC; Lee DA; Muthusamy N; Vasu S
    Cytotherapy; 2020 Jul; 22(7):369-376. PubMed ID: 32303428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterodimeric Bispecific Single Chain Variable Fragments (scFv) Killer Engagers (BiKEs) Enhance NK-cell Activity Against CD133+ Colorectal Cancer Cells.
    Schmohl JU; Gleason MK; Dougherty PR; Miller JS; Vallera DA
    Target Oncol; 2016 Jun; 11(3):353-61. PubMed ID: 26566946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.